Literature DB >> 7451724

Dobutamine, isoprenaline and dopamine in patients after open heart surgery.

J H Chamberlain, J R Pepper, A K Yates.   

Abstract

Dobutamine, a new synthetic catecholamine, has been developed as a more specific inotrope and is reported to have less effect on heart rate and peripheral vascular resistance than other catecholamines. Reports of its effects after cardiotomy have cast doubt on this idea. We have compared the haemodynamic effects of dobutamine with isoprenaline (Group I) and with dopamine (Group II) in early postcardiotomy patients. In both groups a dose response curve was evaluated (dopamine and dobutamine were given at 1.25, 2.5, 5.0 and 10.0 microgram/kg/min; isoprenaline at 0.005, 0.01, 0.02 and 0.04 microgram/kg/min). In Group I both drugs caused significant increases in cardiac index at the highest dose level only. At that level isoprenaline was associated with a significantly higher heart rate than dobutamine and a significantly lower systemic vascular resistance. Similarly, in Group II, both drugs caused significant increases in the cardiac index only at the highest dose level. However, the heart rate at this dose was significantly higher with dobutamine. Dopamine caused no changes in heart rate at any dose level. Neither drug was associated with any alteration of systemic vascular resistance. No changes in stroke volume, left atrial pressure or pulmonary vascular resistance were found in either group. The rise in cardiac output was caused mainly by tachycardia.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7451724     DOI: 10.1007/bf01692914

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  9 in total

1.  A comparison of cardiovascular effects of dobutamine and isoprenaline after open heart surgery.

Authors:  F Kersting; F Follath; R Moulds; J Mucklow; R McCloy; J Sheares; C Dollery
Journal:  Br Heart J       Date:  1976-06

2.  Cardiovascular effects of dobutamine in severe congestive heart failure.

Authors:  J J Andy; C L Curry; N Ali; P P Mehrotra
Journal:  Am Heart J       Date:  1977-08       Impact factor: 4.749

3.  Clinical cardiovascular pharmacology of dobutamine. A selective inotropic catecholamine.

Authors:  D Jewitt; J Birkhead; A Mitchell; C Dollery
Journal:  Lancet       Date:  1974-08-17       Impact factor: 79.321

4.  Integrator for aortic and pulmonary artery flow signals, with automatic zero adjustment and beat-to-beat mean flow computation.

Authors:  F K Dijkema; G Elzinga
Journal:  Cardiovasc Res       Date:  1973-07       Impact factor: 10.787

5.  Dobutamine: development of a new catecholamine to selectively increase cardiac contractility.

Authors:  R R Tuttle; J Mills
Journal:  Circ Res       Date:  1975-01       Impact factor: 17.367

6.  Dobutamine for inotropic support during emergence from cardiopulmonary bypass.

Authors:  J H Tinker; S Tarhan; R D White; J R Pluth; D A Barnhorst
Journal:  Anesthesiology       Date:  1976-04       Impact factor: 7.892

7.  Hemodynamic effects of dobutamine in patients following open heart surgery.

Authors:  T Sakamoto; T Yamada
Journal:  Circulation       Date:  1977-03       Impact factor: 29.690

8.  Comparative systemic and regional hemodynamic effects of dopamine and dobutamine in patients with cardiomyopathic heart failure.

Authors:  C V Leier; P T Heban; P Huss; C A Bush; R P Lewis
Journal:  Circulation       Date:  1978-09       Impact factor: 29.690

9.  Efficacy of dopamine, dobutamine, and epinephrine during emergence from cardiopulmonary bypass in man.

Authors:  P A Steen; J H Tinker; J R Pluth; D A Barnh;rst; S Tarhan
Journal:  Circulation       Date:  1978-02       Impact factor: 29.690

  9 in total
  2 in total

1.  Continuous multi-channel intravascular monitoring of the effects of dopamine and dobutamine on plasma potassium in dogs.

Authors:  H F Drake; M Smith; D R Corfield; T Treasure
Journal:  Intensive Care Med       Date:  1989       Impact factor: 17.440

2.  Comparison of the effects of dopamine and dobutamine during continuous positive-pressure ventilation.

Authors:  M Brandl; T Pasch; H D Kamp; J Grimm
Journal:  Intensive Care Med       Date:  1983       Impact factor: 17.440

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.